Navamedic ASA (OSL:NAVA)

Market Cap	259.00M -49.8%
Revenue (ttm)	556.03M +3.1%
Net Income	-24.95M
EPS	-1.05
Shares Out	23.98M
PE Ratio	n/a
Forward PE	41.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,301
Open	11.00
Previous Close	10.45
Day's Range	10.60 - 11.00
52-Week Range	9.82 - 26.50
Beta	0.25
Analysts	Strong Buy
Price Target	20.63 (+91.02%)
Earnings Date	Oct 29, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 38
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2025, Navamedic ASA's revenue was 565.36 million, an increase of 6.38% compared to the previous year's 531.44 million. Losses were -23.54 million, 329.1% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for NAVA stock is "Strong Buy." The 12-month stock price target is kr 20.63, which is an increase of 91.02% from the latest price.

Price Target

kr 20.63

(91.02% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error